Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report), with a price target of $9.00. The company’s shares closed last Friday at $1.94.

According to TipRanks, Olson is a 5-star analyst with an average return of 17.5% and a 43.33% success rate. Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, ACADIA Pharmaceuticals, and Biogen.

Currently, the analyst consensus on Cognition Therapeutics is a Moderate Buy with an average price target of $7.00.

Based on Cognition Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.14 million. In comparison, last year the company had a GAAP net loss of $5.18 million

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CGTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cognition Therapeutics (CGTX) Company Description:

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.